<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
      <title>
        
            OmniSeq
        
    </title>

     <link rel="stylesheet" type="text/css" href="/Users/mglynias/Desktop/PycharmProjects/nova/static/css/main.css">
    <link href="https://fonts.googleapis.com/css?family=Lato&display=swap" rel="stylesheet">

</head>
<body>


<img src="/Users/mglynias/Desktop/PycharmProjects/nova/static/IntegratedOncology.jpg" width="150" />

<img class="Omniseq_logo" src="/Users/mglynias/Desktop/PycharmProjects/nova/static/omniseqCdx_logo.png" />

<div class="Header_Wrapper">
    <div>PATIENT</div>
     <div >SPECIMEN</div>
    <div >CLIENT</div>
</div>

<div class="Table">
    <div class="Row">
        <div class="Cell">
            <div><strong>Name:&nbsp;</strong>Nathan Duran</div>
            <div><strong>DOB:&nbsp;</strong>01/10/1956&nbsp;&nbsp;&nbsp;<strong>Sex:&nbsp;</strong>Male</div>
            <div><strong>MRN:&nbsp;</strong>987654321<strong>Order ID:&nbsp;</strong>P-19-01715</div>
            <div><strong>Report Date:&nbsp;</strong> 12/13/2019 10:39 AM ET </div>
            <div><strong>Diagnosis:&nbsp;</strong>C18.9, Malignant neoplasm of colon, unspecified</div>
        </div>
        <div class="Cell">
            <div><strong>Facility:&nbsp;</strong>Union Hospital</div>
            <div><strong>ID:&nbsp;</strong>UHH-19-005523 B1 (AGX19-009562)</div>
            <div><strong>Source:&nbsp;</strong> biopsy</div>
            <div><strong>Procured:&nbsp;</strong>04/13/2019</div>
            <div><strong>Collected:&nbsp;</strong>04/13/2019 10:39 AM ET</div>
            <div><strong>Received:&nbsp;</strong>04/23/2019 10:39 AM ET</div>
        </div>
        <div class="Cell">
            <div><strong>Provider:&nbsp;</strong> Brian Pearson&nbsp;MD</div>
            <div><strong>NPI:&nbsp;</strong>678901234</div>
            <div>&nbsp;</div>
            <div><strong>Ordering Facility:&nbsp;</strong>Integrated Oncology Phoenix</div>
            <div>&nbsp;</div>
        </div>
    </div>
</div>

<div class="Vertical_Spacer_10"></div>

<div class="Section_Header">SUMMARY</div>
<div class="Pathologists_Comments">
    This 63 year old man with colorectal cancer has one variant (EGFR amp) with an FDA CDx label.&nbsp;&nbsp; In addition, there  is one potentially actionable variant (ERBB2 amp). &nbsp;&nbsp;The PD-L1 is negative at 0% TPS, the TMB is low at 1.75 Mut/Mb, and MSI is stable.<!----><!---->
</div>

<div class="Vertical_Spacer_10"></div>
<div class="Section_Header">PRIORITY MARKER RESULTS AND THERAPY CONSIDERATIONS FOR THE TESTED SPECIMEN</div>
<div class="Section_Subhead">Colorectal Cancer</div>

<div class="Markers_Wrapper">
    <div>Companion Diagnostic (CDx) Genomic Markers</div>
    <div>
        
            EGFR amp
        
    </div>
    <div>Actionable Genomic Markers</div>
    <div>
        
            ERBB2 amp
        </div>
    <div>Pertinent Negatives: <br/><span class="Markers_Wrapper_Span">(Genomic markers tested but not detected)</span></div>
    <div  class="Pertinent_Negatives">
        
            KRAS G12X, G13X, A146X, A59X, Q61X, K117X, NRAS K117X, G12X, A146X, A59X, G13X, Q61X, NTRK1/2/3 fusions
        
    </div>
    <div>PD-L1 (IHC 22C3) (CDx)</div>
    <div>0% Tumor Proportion Score (TPS)</div>
    <div>Tumor Mutational Burden (TMB)</div>
    <div>1.75 Mut/Mb</div>
    <div>Microsatellite Instability (MSI)</div>
    <div>Stable</div>

</div>

<div class="Vertical_Spacer_10"></div>

<div class="Therapies_Header_Wrapper">
    <div>Positive Markers</div>
    <div>Therapies</div>
    <div>Setting</div>
    <div>Evidence</div>
</div>


<div class="Therapies_Wrapper">
    
        <div class="Therapy_Marker"><div class="Therapy_Marker_Text">KRAS wild-type+NRAS wild-type+EGFR amp</div></div>
        <div class="Nested_Therapies_Wrapper">
            
                <div>panitumumab</div>
                <div>-</div>
                <div>CDx (IA)</div>
            
        </div>
    
        <div class="Therapy_Marker"><div class="Therapy_Marker_Text">KRAS wild-type+NRAS wild-type</div></div>
        <div class="Nested_Therapies_Wrapper">
            
                <div>cetuximab + fluorouracil + irinotecan + leucovorin</div>
                <div>-</div>
                <div>CDx (IA)</div>
            
                <div>cetuximab + irinotecan</div>
                <div>-</div>
                <div>CDx (IA)</div>
            
                <div>cetuximab + fluorouracil + leucovorin + oxaliplatin</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>bevacizumab + cetuximab + fluorouracil + irinotecan + leucovorin</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
        </div>
    
        <div class="Therapy_Marker"><div class="Therapy_Marker_Text">KRAS wild-type</div></div>
        <div class="Nested_Therapies_Wrapper">
            
                <div>cetuximab</div>
                <div>-</div>
                <div>CDx (IA)</div>
            
                <div>bevacizumab</div>
                <div>-</div>
                <div>Phase III (IB)</div>
            
                <div>fluorouracil + irinotecan + oxaliplatin + panitumumab</div>
                <div>-</div>
                <div>Phase III (IB)</div>
            
                <div>bevacizumab + capecitabine</div>
                <div>-</div>
                <div>Phase III (IB)</div>
            
                <div>panitumumab + rilotumumab</div>
                <div>-</div>
                <div>Phase II (IIC)</div>
            
                <div>fluorouracil + leucovorin + necitumumab + oxaliplatin</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>lapatinib + trastuzumab</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>napabucasin + panitumumab</div>
                <div>-</div>
                <div>Phase II (IIC)</div>
            
                <div>cabozantinib + panitumumab</div>
                <div>-</div>
                <div>Phase II (IIC)</div>
            
                <div>sym004</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
        </div>
    
        <div class="Therapy_Marker"><div class="Therapy_Marker_Text">ERBB2 amp</div></div>
        <div class="Nested_Therapies_Wrapper">
            
                <div>neratinib</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>pertuzumab + trastuzumab</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>afatinib</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>ado-trastuzumab emtansine</div>
                <div>-</div>
                <div>Phase II (IB)</div>
            
                <div>capecitabine + lapatinib + oxaliplatin</div>
                <div>Off Label</div>
                <div>Phase II (IB)</div>
            
        </div>
    
        <div class="Therapy_Marker"><div class="Therapy_Marker_Text">EGFR amp</div></div>
        <div class="Nested_Therapies_Wrapper">
            
                <div>depatuxizumab mafodotin</div>
                <div>-</div>
                <div>Phase II (IIC)</div>
            
        </div>
    
</div>

<div class="Vertical_Spacer_10"></div>
<div class="Cap_Asco_Blurb">
Priority tumor profiling results include markers associated with therapies with AMP/CAP/ASCO Level IA (on-label or included in professional guidelines) or IB (well-powered studies with consensus in the field). See Therapy Details for more information and additional treatment considerations, including clinical trials.
</div>




<div class="Footer">
     P-19-01715-150&nbsp;P-20-00000-000 VERSION 1 | Report electronically signed by George Who, MD
    |12/13/2019 10:39 AM ET <br>
    CLIA ID: 33D2098748 | CAP # 9405346 | OmniSeq Inc., 700 Ellicott Street, Buffalo NY 14203 | 1 (800) 781-1259
<img class="Cap_logo" src="/Users/mglynias/Desktop/PycharmProjects/nova/static/cap_logo.png" width="75" />

</div>

</body>
</html>
